REGN Stock Analysis — Regeneron Pharmaceuticals
Sector: Healthcare
AI Verdict
Regeneron is cheap for the growth you're getting, and the antibody platform moat makes the 31.3% earnings jump look credible, but the high RSI means short-term buyers face real pullback risk.
Competitive Moat
Regeneron develops biologic drugs for serious diseases, anchored by proprietary antibody discovery platforms like VelocImmune that enable rapid pipeline expansion. Their deep expertise in monoclonal antibody engineering and a strong patent portfolio create high barriers for competitors.
Summary
Regeneron trades at 12.3x forward earnings with consensus calling for 31.3% EPS growth, a rare combination in large-cap biotech.
Where It Stands
Shares are up 21.02% over the past year, the RSI is elevated at 69.6 (pullback risk), and the stock trades at 12.3x forward earnings versus a healthcare median of 22x.
Key Metrics
- RSI: 69.6 — Near Overbought
- Trailing P/E: 16.2x
- Forward P/E: 12.3x
- PEG Ratio: 0.49
- Earnings Growth: +0.3%
- Revenue Growth: +0.1%
- Market Cap: $69.5B
- Dividend Yield: 0.01%
- 1-Year Return: 21.02%
- 52-Week High: $821.11
- 52-Week Low: $532.60
Analyst Consensus
27 Buy · 11 Hold · 0 Sell (38 analysts)
Bull Case
You're paying just 12.3x next year's earnings for a company expected to grow EPS by 31.3%, which is cheap for this level of growth.
Bear Case
With an RSI of 69.6, the stock is at elevated risk of a short-term pullback if sentiment cools, which could mean a 10–15% drop just to reset momentum.
Catalyst to Watch
Upcoming clinical trial readouts or FDA approvals could validate the growth outlook and justify the low forward multiple.